Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Volume 218, Issue -, Pages 394-408
Publisher
Elsevier BV
Online
2022-07-23
DOI
10.1016/j.ijbiomac.2022.07.156
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of pH on the structure and function of cyclin-dependent kinase 6
- (2022) Mohd Yousuf et al. PLoS One
- CDK4 and CDK6 kinases: From basic science to cancer therapy
- (2022) Anne Fassl et al. SCIENCE
- Natural products can be used in therapeutic management of COVID-19: Probable mechanistic insights
- (2022) Sabeeha Ali et al. BIOMEDICINE & PHARMACOTHERAPY
- Epigallocatechin 3-gallate: From green tea to cancer therapeutics
- (2022) Manzar Alam et al. FOOD CHEMISTRY
- Therapeutic targeting of TANK-binding kinase signaling towards anticancer drug development: Challenges and opportunities
- (2022) Manzar Alam et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Investigating the Mechanism of Inhibition of Cyclin-Dependent Kinase 6 Inhibitory Potential by Selonsertib: Newer Insights Into Drug Repurposing
- (2022) Mohammad Hassan Baig et al. Frontiers in Oncology
- Therapeutic Implications of Caffeic Acid in Cancer and Neurological Diseases
- (2022) Manzar Alam et al. Frontiers in Oncology
- Naringenin as a potential inhibitor of human cyclin-dependent kinase 6: Molecular and structural insights into anti-cancer therapeutics
- (2022) Mohd Yousuf et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Therapeutic implications and clinical manifestations of thymoquinone
- (2022) Manzar Alam et al. PHYTOCHEMISTRY
- Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines
- (2021) Bashir Lawal et al. Biomedicines
- Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
- (2021) Carmine De Angelis et al. CLINICAL CANCER RESEARCH
- Targeting the Sphingosine Kinase/Sphingosine-1-Phosphate Signaling Axis in Drug Discovery for Cancer Therapy
- (2021) Preeti Gupta et al. Cancers
- Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy
- (2021) Saleha Anwar et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Potential therapeutic targets of Klebsiella pneumoniae: a multi-omics review perspective
- (2021) Sabeeha Ali et al. Briefings in Functional Genomics
- A review on the role of TANK-binding kinase 1 signaling in cancer
- (2021) Manzar Alam et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer
- (2021) Manzar Alam et al. LIFE SCIENCES
- Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects
- (2021) Aanchal Rathi et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Therapeutic Potential of Ursolic Acid in Cancer and Diabetic Neuropathy Diseases
- (2021) Manzar Alam et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
- (2021) Manzar Alam et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CTLA-4: From mechanism to autoimmune therapy
- (2020) Arezoo Hosseini et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Chemotherapy and CDK4/6 Inhibition in Cancer Treatment: Timing Is Everything
- (2020) Anne Fassl et al. CANCER CELL
- CDK4/6 inhibitors in P16/HPV16-negative squamous cell carcinoma of the head and neck
- (2020) Camelia Billard-Sandu et al. EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
- The role of CDK6 in cancer
- (2020) Sofie Nebenfuehr et al. INTERNATIONAL JOURNAL OF CANCER
- Ellagic Acid Controls Cell Proliferation and Induces Apoptosis in Breast Cancer Cells via Inhibition of Cyclin-Dependent Kinase 6
- (2020) Mohd Yousuf et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Restriction point regulation at the crossroads between quiescence and cell proliferation
- (2020) Betheney R. Pennycook et al. FEBS LETTERS
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- (2020) Stephen R. D. Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrating Old and New Paradigms of G1/S Control
- (2020) Seth M. Rubin et al. MOLECULAR CELL
- Regulation of glycolysis by non-coding RNAs in cancer: Switching on the Warburg effect
- (2020) Hamed Mirzaei et al. Molecular Therapy-Oncolytics
- Inhibiting CDK6 Activity by Quercetin Is an Attractive Strategy for Cancer Therapy
- (2020) Mohd Yousuf et al. ACS Omega
- Properties of FDA-approved small molecule protein kinase inhibitors
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Preclinical characterization of SHR 6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models
- (2019) Fei Long et al. CANCER SCIENCE
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- Practical treatment strategies and future directions after progression on CDK4/6 inhibition and endocrine therapy in advanced HR+/HER2- breast cancer
- (2019) Sarah Sammons et al. Clinical Breast Cancer
- Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
- (2019) Jiayi Yu et al. CLINICAL CANCER RESEARCH
- Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation
- (2019) Mara Bonelli et al. BIOCHEMICAL PHARMACOLOGY
- Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
- (2019) Dennis J. Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
- (2019) Keelan Z. Guiley et al. SCIENCE
- The Pentose Phosphate Pathway as a Potential Target for Cancer Therapy
- (2018) Eunae Sandra Cho et al. Biomolecules & Therapeutics
- CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
- (2018) Mary E. Klein et al. CANCER CELL
- Phosphorylation-induced changes in the energetic frustration in human Tank binding kinase 1
- (2018) Shahrukh Husain et al. JOURNAL OF THEORETICAL BIOLOGY
- Metabolic Kinases Moonlighting as Protein Kinases
- (2018) Zhimin Lu et al. TRENDS IN BIOCHEMICAL SCIENCES
- CDK6 inhibits white to beige fat transition by suppressing RUNX1
- (2018) Xiaoli Hou et al. Nature Communications
- Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
- (2018) Silvia Paola Corona et al. Drug Design Development and Therapy
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer
- (2017) Angela Chou et al. GUT
- Binding studies and biological evaluation of β-carotene as a potential inhibitor of human calcium/calmodulin-dependent protein kinase IV
- (2017) Huma Naz et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Cell-Cycle Therapeutics Come of Age
- (2017) Matthew Ingham et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding cell cycle and cell death regulation provides novel weapons against human diseases
- (2017) K. G. Wiman et al. JOURNAL OF INTERNAL MEDICINE
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival
- (2017) Haizhen Wang et al. NATURE
- Cancer immunotherapy: Cell cycle inhibitors boost tumour immunogenicity
- (2017) Kirsty Minton NATURE REVIEWS DRUG DISCOVERY
- Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein
- (2017) Stella Hernandez Maganhi et al. PROTEIN SCIENCE
- A subcellular map of the human proteome
- (2017) Peter J. Thul et al. SCIENCE
- A pathology atlas of the human cancer transcriptome
- (2017) Mathias Uhlen et al. SCIENCE
- Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
- (2017) Esther S. Kim et al. Targeted Oncology
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Glycogen synthase kinase-3β mediated regulation of matrix metalloproteinase-9 and its involvement in oral squamous cell carcinoma progression and invasion
- (2017) Kamdeo K. Pramanik et al. CELLULAR ONCOLOGY
- Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
- (2017) Erik S. Knudsen et al. Oncotarget
- CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease
- (2017) Juliann E. Kosovec et al. Oncotarget
- Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System
- (2017) Stephen T. Hallett et al. Cell Reports
- Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer
- (2017) Mark L. Zangardi et al. Expert Review of Clinical Pharmacology
- Cell cycle regulation and anticancer drug discovery
- (2017) Bai Jingwen et al. Cancer Biology & Medicine
- 455PPHASE I STUDY OF LEE011 (CDK4/6 INHIBITOR) IN PATIENTS WITH MALIGNANT RHABDOID TUMORS, NEUROBLASTOMA, AND CYCLIN D–CDK4/6 PATHWAY-ACTIVATED TUMORS
- (2017) B. Geoerger et al. ANNALS OF ONCOLOGY
- Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients
- (2016) Myrella Vlenterie et al. ANNALS OF SURGICAL ONCOLOGY
- Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
- (2016) Romualdo Barroso-Sousa et al. Breast Care
- Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6
- (2016) A. Yoshida et al. CANCER RESEARCH
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Targeting CDK4/6 in patients with cancer
- (2016) Erika Hamilton et al. CANCER TREATMENT REVIEWS
- A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
- (2016) J. R. Infante et al. CLINICAL CANCER RESEARCH
- Cancer metabolism at a glance
- (2016) Alexei Vazquez et al. JOURNAL OF CELL SCIENCE
- CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1
- (2016) Anuja Sathe et al. JOURNAL OF UROLOGY
- Phosphoribosyl Diphosphate (PRPP): Biosynthesis, Enzymology, Utilization, and Metabolic Significance
- (2016) Bjarne Hove-Jensen et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- Protein kinases: mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance
- (2016) Kalyana C. Nandipati et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics
- (2016) Teresa Helsten et al. MOLECULAR CANCER THERAPEUTICS
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cyclin-Dependent Kinases as Coregulators of Inflammatory Gene Expression
- (2016) M. Lienhard Schmitz et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Reversion-inducing cysteine-rich protein with Kazal motifs and its regulation by glycogen synthase kinase 3 signaling in oral cancer
- (2016) Kamdeo K. Pramanik et al. TUMOR BIOLOGY
- Palbociclib (PD0332991)—a Selective and Potent Cyclin-Dependent Kinase Inhibitor
- (2016) Amy S. Clark et al. JAMA Oncology
- Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor Palbociclib
- (2016) Mark A. Dickson et al. JAMA Oncology
- Fundamentals of cancer metabolism
- (2016) R. J. DeBerardinis et al. Science Advances
- Cyclin dependent kinase (CDK) inhibitors as anticancer drugs
- (2015) Concepción Sánchez-Martínez et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway
- (2015) Adrian von Witzleben et al. CANCER RESEARCH
- Targeting CDK6 in cancer: State of the art and new insights
- (2015) Solomon Tadesse et al. CELL CYCLE
- AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow
- (2015) Yusuke Saito et al. Cell Stem Cell
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tissue-based map of the human proteome
- (2015) M. Uhlen et al. SCIENCE
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
- (2015) Agnieszka K. Witkiewicz et al. Oncotarget
- MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
- (2015) Marta Kovatcheva et al. Oncotarget
- CDK6 and p16INK4a in lymphoid malignancies
- (2015) Karoline Kollmann et al. Oncotarget
- CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
- (2015) Jorge Franco et al. Oncotarget
- Phylogenetic analysis of CDK and cyclin proteins in premetazoan lineages
- (2014) Lihuan Cao et al. BMC EVOLUTIONARY BIOLOGY
- CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers
- (2014) A. M. Heilmann et al. CANCER RESEARCH
- Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts
- (2014) S. C. Tate et al. CLINICAL CANCER RESEARCH
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
- The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
- (2014) V. Yadav et al. MOLECULAR CANCER THERAPEUTICS
- Antiproliferative Effects of CDK4/6 Inhibition in CDK4-Amplified Human Liposarcoma In Vitro and In Vivo
- (2014) Y.-X. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Cyclin-Dependent Kinase 6 Is a Chromatin-Bound Cofactor for NF-κB-Dependent Gene Expression
- (2014) Katja Handschick et al. MOLECULAR CELL
- Cyclin-dependent kinases
- (2014) Marcos Malumbres GENOME BIOLOGY
- CDK4 inhibition restores G₁-S arrest inMYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage
- (2013) Sina Gogolin et al. CELL CYCLE
- RETRACTED ARTICLE: Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy
- (2013) Zhuan Zhou et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Signaling through cyclin D-dependent kinases
- (2013) Y J Choi et al. ONCOGENE
- The ErbB/HER family of protein-tyrosine kinases and cancer
- (2013) Robert Roskoski PHARMACOLOGICAL RESEARCH
- PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma
- (2013) Kelly L. Barton et al. PLoS One
- Signaling Pathways that Control Cell Proliferation
- (2013) R. J. Duronio et al. Cold Spring Harbor Perspectives in Biology
- Protein kinase C signaling and cell cycle regulation
- (2013) Adrian R. Black et al. Frontiers in Immunology
- Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
- (2012) J. P. Leonard et al. BLOOD
- Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
- (2012) Jeffry L. Dean et al. CELL CYCLE
- CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
- (2012) A. Kathleen McClendon et al. CELL CYCLE
- Regulation of p27Kip1by mitogen-induced tyrosine phosphorylation
- (2012) Heidelinde Jäkel et al. CELL CYCLE
- Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
- (2012) Patrick J. Roberts et al. JNCI-Journal of the National Cancer Institute
- Cdk4/6 Inhibition Induces Epithelial-Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
- (2012) F. Liu et al. MOLECULAR CANCER THERAPEUTICS
- p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
- (2012) L. Cen et al. NEURO-ONCOLOGY
- Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma
- (2012) David Lindgren et al. PLoS One
- Cyclin-Dependent Kinase 6 Phosphorylates NF-κB P65 at Serine 536 and Contributes to the Regulation of Inflammatory Gene Expression
- (2012) Holger Buss et al. PLoS One
- Discovery of a Potential Allosteric Ligand Binding Site in CDK2
- (2011) Stephane Betzi et al. ACS Chemical Biology
- A Systematic Screen for CDK4/6 Substrates Links FOXM1 Phosphorylation to Senescence Suppression in Cancer Cells
- (2011) Lars Anders et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
- (2011) Gottfried E. Konecny et al. CLINICAL CANCER RESEARCH
- Evolution of networks and sequences in eukaryotic cell cycle control
- (2011) F. R. Cross et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
- Anti-Inflammatory Effects of Gomisin N, Gomisin J, and Schisandrin C Isolated from the Fruit ofSchisandra chinensis
- (2010) Su-Yeon OH et al. BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
- (2010) K. Michaud et al. CANCER RESEARCH
- miR-129 regulates cell proliferation by downregulating Cdk6 expression
- (2010) Junjie Wu et al. CELL CYCLE
- Whether to target single or multiple CDKs for therapy? That is the question
- (2010) Józefa Węsierska-Gądek et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Towards a knowledge-based Human Protein Atlas
- (2010) Mathias Uhlen et al. NATURE BIOTECHNOLOGY
- Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy
- (2010) Jordi Barretina et al. NATURE GENETICS
- Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
- (2010) W. R. Wiedemeyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective Cyclin-Dependent Kinase Inhibitors Discriminating between Cell Cycle and Transcriptional Kinases
- (2009) Józefa Węsierska-Gądek et al. Annals of the New York Academy of Sciences
- The mitochondrial death pathway: a promising therapeutic target in diseases
- (2009) Sanjeev Gupta et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Cyclin-dependent kinases: a family portrait
- (2009) Marcos Malumbres et al. NATURE CELL BIOLOGY
- CDK9 a Potential Target for Drug Development
- (2008) Fernanda Canduri et al. Medicinal Chemistry
- A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies
- (2008) Lisa Berglund et al. MOLECULAR & CELLULAR PROTEOMICS
- p27Kip1 Inhibits Cyclin D-Cyclin-Dependent Kinase 4 by Two Independent Modes
- (2008) A. Ray et al. MOLECULAR AND CELLULAR BIOLOGY
- Cell cycle control as a basis for cancer chemoprevention through dietary agents
- (2007) Syed Musthapa Meeran Frontiers in Bioscience-Landmark
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now